{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:07:47Z","timestamp":1793844467844,"version":"4.6.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Therapy with elexacaftor\/tezacaftor\/ivacaftor (ETI) works to improve the functionality of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein and has revolutionized CF treatment. However, the implications of ETI for airway barrier and systemic T cell immunobiology remain relatively little studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Here, we investigated the immunological effects of ETI at systemic and local pulmonary levels, using paired peripheral blood and sputum sampling, in relation to key clinical parameters. Samples were taken longitudinally at baseline (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200927), and at three (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200924) and 12\u00a0months (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200919) of treatment and subjected to analysis by advanced flow cytometry, T cell assays, and plasma proteomics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Before ETI treatment initiation, immune cell composition in the sputum closely reflected the plasma inflammatory proteome. T cell abundance in sputum correlated inversely with multiple plasma factors, including IL-17A, IL-8, HGF and TGF\u03b1, and with lower sweat chloride concentrations. Chronic microbial infection was associated with low abundance of CD4 T cells and mucosa-associated invariant T (MAIT) cells in sputum samples collected at baseline. During ETI treatment, T cells with lung resident characteristics including MAIT cells increased in sputum, accompanied by improved lung function and reduced systemic inflammation. In peripheral blood, the effector-memory CD8 and CD4 T cell pool expanded and the magnitude and quality of T cell responses to Influenza A virus recovered during ETI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings indicate that ETI treatment promotes immunological remodelling in both airways and circulation, correlating with favorable changes in clinically relevant parameters, and a shift towards healthy immune regulation in the lung and improved adaptive T cell responses in circulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-026-03521-9","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:06:03Z","timestamp":1769123163000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic and airway T cell dynamics with influenza-specific immune recovery by cystic fibrosis elexacaftor\/tezacaftor\/ivacaftor therapy"],"prefix":"10.1186","volume":"27","author":[{"given":"Elli","family":"Mouchtaridi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Kowalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa J. M.","family":"Raineri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"J\u00e4gerstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Bojarlind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Flodstr\u00f6m-Tullberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terezia","family":"Pincikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan K.","family":"Sandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"issue":"10290","key":"3521_CR1","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","volume":"397","author":"M Shteinberg","year":"2021","unstructured":"Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021;397(10290):2195\u2013211.","journal-title":"Lancet"},{"issue":"10059","key":"3521_CR2","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519\u201331.","journal-title":"Lancet"},{"issue":"4\u20136","key":"3521_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00281-024-01003-y","volume":"45","author":"T Kageyama","year":"2024","unstructured":"Kageyama T, Ito T, Tanaka S, Nakajima H. Physiological and immunological barriers in the lung. Semin Immunopathol. 2024;45(4\u20136):533\u201347.","journal-title":"Semin Immunopathol"},{"issue":"6","key":"3521_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41577-020-00477-9","volume":"21","author":"RJ Hewitt","year":"2021","unstructured":"Hewitt RJ, Lloyd CM. Regulation of immune responses by the airway epithelial cell landscape. Nat Rev Immunol. 2021;21(6):347\u201362.","journal-title":"Nat Rev Immunol"},{"issue":"Suppl 2","key":"3521_CR5","first-page":"S177","volume":"13","author":"MA Mall","year":"2016","unstructured":"Mall MA. Unplugging mucus in cystic fibrosis and chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2016;13(Suppl 2):S177\u201385.","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"3521_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jcf.2015.03.003","volume":"14","author":"AM Cantin","year":"2015","unstructured":"Cantin AM, Hartl D, Konstan MW, Chmiel JF. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros. 2015;14(4):419\u201330.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"3521_CR7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1128\/CDLI.6.2.260-265.1999","volume":"6","author":"JM Wolter","year":"1999","unstructured":"Wolter JM, Rodwell RL, Bowler SD, McCormack JG. Cytokines and inflammatory mediators do not indicate acute infection in cystic fibrosis. Clin Diagn Lab Immunol. 1999;6(2):260\u20135.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"12","key":"3521_CR8","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/thoraxjnl-2013-203204","volume":"68","author":"M Cohen-Cymberknoh","year":"2013","unstructured":"Cohen-Cymberknoh M, Kerem E, Ferkol T, Elizur A. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax. 2013;68(12):1157\u201362.","journal-title":"Thorax"},{"issue":"2","key":"3521_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1136\/thoraxjnl-2011-200585","volume":"67","author":"N Regamey","year":"2012","unstructured":"Regamey N, Tsartsali L, Hilliard TN, Fuchs O, Tan HL, Zhu J, et al. Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis. Thorax. 2012;67(2):164\u201370.","journal-title":"Thorax"},{"issue":"11","key":"3521_CR10","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.4049\/jimmunol.1500312","volume":"194","author":"SA Ingersoll","year":"2015","unstructured":"Ingersoll SA, Laval J, Forrest OA, Preininger M, Brown MR, Arafat D, et al. Mature cystic fibrosis airway neutrophils suppress T cell function: evidence for a role of arginase 1 but not programmed death-ligand 1. J Immunol. 2015;194(11):5520\u20138.","journal-title":"J Immunol"},{"issue":"1","key":"3521_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0091-6749(88)90054-1","volume":"82","author":"R Zeaske","year":"1988","unstructured":"Zeaske R, Bruns WT, Fink JN, Greenberger PA, Colby H, Liotta JL, et al. Immune responses to Aspergillus in cystic fibrosis. J Allergy Clin Immunol. 1988;82(1):73\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"3521_CR12","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.4049\/jimmunol.162.4.2347","volume":"162","author":"M Laan","year":"1999","unstructured":"Laan M, Cui ZH, Hoshino H, Lotvall J, Sjostrand M, Gruenert DC, et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol. 1999;162(4):2347\u201352.","journal-title":"J Immunol"},{"issue":"5","key":"3521_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1034\/j.1600-0463.2000.d01-64.x","volume":"108","author":"C Moser","year":"2000","unstructured":"Moser C, Kjaergaard S, Pressler T, Kharazmi A, Koch C, Hoiby N. The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. APMIS. 2000;108(5):329\u201335.","journal-title":"APMIS"},{"issue":"6","key":"3521_CR14","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1165\/ajrcmb.26.6.4757","volume":"26","author":"CE Jones","year":"2002","unstructured":"Jones CE, Chan K. Interleukin-17 stimulates the expression of interleukin-8, growth-related oncogene-alpha, and granulocyte-colony-stimulating factor by human airway epithelial cells. Am J Respir Cell Mol Biol. 2002;26(6):748\u201353.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"3521_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1164\/rccm.201206-1150OC","volume":"187","author":"K Tiringer","year":"2013","unstructured":"Tiringer K, Treis A, Fucik P, Gona M, Gruber S, Renner S, et al. A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2013;187(6):621\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"3521_CR16","doi-asserted-by":"crossref","unstructured":"Schwarz C, Eschenhagen P, Schmidt H, Hohnstein T, Iwert C, Grehn C, et al. Antigen specificity and cross-reactivity drive functionally diverse anti-Aspergillus fumigatus T cell responses in cystic fibrosis. J Clin Invest. 2023;133(5):e161593.","DOI":"10.1172\/JCI161593"},{"issue":"4","key":"3521_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1513\/AnnalsATS.202306-576OC","volume":"21","author":"CS Thornton","year":"2024","unstructured":"Thornton CS, Caverly LJ, Kalikin LM, Carmody LA, McClellan S, LeBar W, et al. Prevalence and clinical impact of respiratory viral infections from the STOP2 study of cystic fibrosis pulmonary exacerbations. Ann Am Thorac Soc. 2024;21(4):595\u2013603.","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"3521_CR18","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/cid\/cix203","volume":"64","author":"R Somayaji","year":"2017","unstructured":"Somayaji R, Goss CH, Khan U, Neradilek M, Neuzil KM, Ortiz JR. Cystic fibrosis pulmonary exacerbations attributable to respiratory syncytial virus and influenza: a population-based study. Clin Infect Dis. 2017;64(12):1760\u20137.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3521_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220\u201331.","journal-title":"N Engl J Med"},{"issue":"19","key":"3521_CR20","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, Drevinek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019;381(19):1809\u201319.","journal-title":"N Engl J Med"},{"issue":"10212","key":"3521_CR21","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940\u20138.","journal-title":"Lancet"},{"issue":"6","key":"3521_CR22","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1164\/rccm.202210-1938LE","volume":"207","author":"A Lepissier","year":"2023","unstructured":"Lepissier A, Bonnel AS, Wizla N, Weiss L, Mittaine M, Bessaci K, et al. Moving the dial on airway inflammation in response to Trikafta in adolescents with cystic fibrosis. Am J Respir Crit Care Med. 2023;207(6):792\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"3521_CR23","doi-asserted-by":"publisher","first-page":"1486784","DOI":"10.3389\/fimmu.2025.1486784","volume":"16","author":"H Ozuna","year":"2025","unstructured":"Ozuna H, Bojja D, Partida-Sanchez S, Hall-Stoodley L, Amer A, Britt RD Jr, et al. Proteomics profiling of inflammatory responses to elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis. Front Immunol. 2025;16:1486784.","journal-title":"Front Immunol"},{"issue":"8","key":"3521_CR24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/thorax-2022-219943","volume":"78","author":"M Casey","year":"2023","unstructured":"Casey M, Gabillard-Lefort C, McElvaney OF, McElvaney OJ, Carroll T, Heeney RC, et al. Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis. Thorax. 2023;78(8):835\u20139.","journal-title":"Thorax"},{"issue":"5","key":"3521_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304555","volume":"19","author":"HH Jarosz-Griffiths","year":"2024","unstructured":"Jarosz-Griffiths HH, Gillgrass L, Caley LR, Spoletini G, Clifton IJ, Etherington C, et al. Anti-inflammatory effects of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis heterozygous for F508del. PLoS ONE. 2024;19(5):e0304555.","journal-title":"PLoS ONE"},{"issue":"1","key":"3521_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e23428","volume":"10","author":"D Westholter","year":"2024","unstructured":"Westholter D, Pipping J, Raspe J, Schmitz M, Sutharsan S, Strassburg S, et al. Plasma levels of chemokines decrease during elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis. Heliyon. 2024;10(1):e23428.","journal-title":"Heliyon"},{"key":"3521_CR27","doi-asserted-by":"crossref","unstructured":"Morgan SJ, Coulter E, Betts HL, Solomon GM, Clancy JP, Rowe SM, et al. Elexacaftor\/tezacaftor\/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment. J Clin Invest. 2024;134(20):e184171.","DOI":"10.1172\/JCI184171"},{"issue":"2","key":"3521_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/cyto.a.21015","volume":"79","author":"M Roederer","year":"2011","unstructured":"Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A. 2011;79(2):167\u201374.","journal-title":"Cytometry A"},{"issue":"27","key":"3521_CR29","doi-asserted-by":"publisher","first-page":"E5434","DOI":"10.1073\/pnas.1705759114","volume":"114","author":"J Dias","year":"2017","unstructured":"Dias J, Leeansyah E, Sandberg JK. Multiple layers of heterogeneity and subset diversity in human MAIT cell responses to distinct microorganisms and to innate cytokines. Proc Natl Acad Sci U S A. 2017;114(27):E5434\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"3521_CR30","doi-asserted-by":"publisher","first-page":"588","DOI":"10.2183\/pjab.86.588","volume":"86","author":"T Nakamura","year":"2010","unstructured":"Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(6):588\u2013610.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"Pt 2","key":"3521_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.143212","volume":"310","author":"S Gaba","year":"2025","unstructured":"Gaba S, Sahu M, Chauhan N, Jain U. Transforming growth factor alpha: Key insights into physiological role, cancer therapeutics, and biomarker potential (A review). Int J Biol Macromol. 2025;310(Pt 2):143212.","journal-title":"Int J Biol Macromol"},{"key":"3521_CR32","doi-asserted-by":"crossref","unstructured":"Salou M, Paiva RA, Lantz O. Development and Functions of MAIT Cells. Annu Rev Immunol. 2025;43(1):253\u2013283.","DOI":"10.1146\/annurev-immunol-082323-025943"},{"issue":"99","key":"3521_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adn2362","volume":"9","author":"T Kammann","year":"2024","unstructured":"Kammann T, Cai C, Sekine T, Mouchtaridi E, Boulouis C, Nilsen V, et al. MAIT cell heterogeneity across paired human tissues reveals specialization of distinct regulatory and enhanced effector profiles. Sci Immunol. 2024;9(99):eadn2362.","journal-title":"Sci Immunol"},{"key":"3521_CR34","doi-asserted-by":"crossref","unstructured":"Dhote T, Martin C, Regard L, Pesenti L, Kanaan R, Carlier N, et al. Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosis. The European respiratory journal. 2023;61(1):2202096.","DOI":"10.1183\/13993003.02096-2022"},{"issue":"5","key":"3521_CR35","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/hep.1840120517","volume":"12","author":"JV Castell","year":"1990","unstructured":"Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12(5):1179\u201386.","journal-title":"Hepatology"},{"issue":"5","key":"3521_CR36","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1165\/rcmb.2002-0272OC","volume":"29","author":"TD Starner","year":"2003","unstructured":"Starner TD, Barker CK, Jia HP, Kang Y, McCray PB Jr. CCL20 is an inducible product of human airway epithelia with innate immune properties. Am J Respir Cell Mol Biol. 2003;29(5):627\u201333.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"3521_CR37","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1183\/09031936.00178508","volume":"34","author":"S Brennan","year":"2009","unstructured":"Brennan S, Sly PD, Gangell CL, Sturges N, Winfield K, Wikstrom M, et al. Alveolar macrophages and CC chemokines are increased in children with cystic fibrosis. Eur Respir J. 2009;34(3):655\u201361.","journal-title":"Eur Respir J"},{"key":"3521_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.619442","volume":"12","author":"M Veltman","year":"2021","unstructured":"Veltman M, De Sanctis JB, Stolarczyk M, Klymiuk N, Bahr A, Brouwer RW, et al. Cftr correctors and antioxidants partially normalize lipid imbalance but not abnormal basal inflammatory cytokine profile in CF bronchial epithelial cells. Front Physiol. 2021;12:619442.","journal-title":"Front Physiol"},{"issue":"10","key":"3521_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140979","volume":"10","author":"V Balloy","year":"2015","unstructured":"Balloy V, Varet H, Dillies MA, Proux C, Jagla B, Coppee JY, et al. Normal and cystic fibrosis human bronchial epithelial cells infected with Pseudomonas aeruginosa exhibit distinct gene activation patterns. PLoS ONE. 2015;10(10):e0140979.","journal-title":"PLoS ONE"},{"issue":"5","key":"3521_CR40","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jcf.2009.06.001","volume":"8","author":"M Roderfeld","year":"2009","unstructured":"Roderfeld M, Rath T, Schulz R, Seeger W, Tschuschner A, Graf J, et al. Serum matrix metalloproteinases in adult CF patients: relation to pulmonary exacerbation. J Cyst Fibros. 2009;8(5):338\u201347.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"3521_CR41","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1203\/00006450-199308000-00010","volume":"34","author":"TP Dean","year":"1993","unstructured":"Dean TP, Dai Y, Shute JK, Church MK, Warner JO. Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. Pediatr Res. 1993;34(2):159\u201361.","journal-title":"Pediatr Res"},{"issue":"3","key":"3521_CR42","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1526-0542(03)00059-9","volume":"4","author":"D Wat","year":"2003","unstructured":"Wat D, Doull I. Respiratory virus infections in cystic fibrosis. Paediatr Respir Rev. 2003;4(3):172\u20137.","journal-title":"Paediatr Respir Rev"},{"key":"3521_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03067","volume":"9","author":"MR Kiedrowski","year":"2018","unstructured":"Kiedrowski MR, Bomberger JM. Viral-bacterial co-infections in the cystic fibrosis respiratory tract. Front Immunol. 2018;9:3067.","journal-title":"Front Immunol"},{"key":"3521_CR44","doi-asserted-by":"crossref","unstructured":"Earnhardt EY, Tipper JL, D'Mello A, Jian MY, Conway ES, Mobley JA, et al. Influenza A-induced cystic fibrosis transmembrane conductance regulator dysfunction increases susceptibility to Streptococcus pneumoniae. JCI insight. 2023;8(14):e170022.","DOI":"10.1172\/jci.insight.170022"},{"issue":"4","key":"3521_CR45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.4049\/jimmunol.2300147","volume":"211","author":"JK Sandberg","year":"2023","unstructured":"Sandberg JK, Leeansyah E, Eller MA, Shacklett BL, Paquin-Proulx D. The emerging role of MAIT cell responses in viral infections. J Immunol. 2023;211(4):511\u20137.","journal-title":"J Immunol"},{"key":"3521_CR46","doi-asserted-by":"crossref","unstructured":"Germain L, Veloso P, Lantz O, Legoux F. MAIT cells: Conserved watchers on the wall. J Exp Med. 2025;222(1):e20232298.","DOI":"10.1084\/jem.20232298"},{"issue":"5","key":"3521_CR47","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1016\/j.chest.2018.01.020","volume":"153","author":"T Pincikova","year":"2018","unstructured":"Pincikova T, Paquin-Proulx D, Moll M, Flodstrom-Tullberg M, Hjelte L, Sandberg JK. Severely impaired control of bacterial infections in a patient with cystic fibrosis defective in mucosal-associated invariant T cells. Chest. 2018;153(5):e93\u20136.","journal-title":"Chest"},{"issue":"2","key":"3521_CR48","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1164\/rccm.202401-0201LE","volume":"210","author":"E Bardin","year":"2024","unstructured":"Bardin E, Dietrich C, Attailia M, Ferroni A, Jamet A, Lezmi G, et al. Restored cytokine-producing capacities of mucosal-associated invariant T cells in pediatric cystic fibrosis patients treated with elexacaftor\/tezacaftor\/ivacaftor. Am J Respir Crit Care Med. 2024;210(2):243\u20135.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3521_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12931-022-02045-2","volume":"23","author":"T Pincikova","year":"2022","unstructured":"Pincikova T, Parrot T, Hjelte L, Hogman M, Lisspers K, Stallberg B, et al. MAIT cell counts are associated with the risk of hospitalization in COPD. Respir Res. 2022;23(1):127.","journal-title":"Respir Res"},{"issue":"1","key":"3521_CR50","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12931-023-02630-z","volume":"24","author":"C Martin","year":"2023","unstructured":"Martin C, Guzior DV, Gonzalez CT, Okros M, Mielke J, Padillo L, et al. Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy. Respir Res. 2023;24(1):317.","journal-title":"Respir Res"},{"key":"3521_CR51","doi-asserted-by":"crossref","unstructured":"Pollak M, Gambazza S, Orenti A, De Rose V, Prais D, Kerem E, et al. Respiratory infections after elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis: analysis of the European Cystic Fibrosis Society Patient Registry. ERJ Open Res. 2025;11(4):01248\u20132024.","DOI":"10.1183\/23120541.01248-2024"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03521-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03521-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03521-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:59:24Z","timestamp":1781629164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03521-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3521"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03521-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7912659\/v1","asserted-by":"object"}]},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Swedish Ethical Review Authority (No 2022\u201306681-01) and performed in accordance with the Declaration of Helsinki. Written informed consent was given by all participants or their legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}